

**The listing of claims presented below replaces all prior versions and listing of claims in the application.**

**Listing of claims:**

1. (Currently amended) A water-soluble fullerene polycarboxylic acid salt of a pharmaceutically acceptable cation wherein the anion is of the general formula



where  $C_{60}$  is the fullerene core,

$NH(CH_2)_mC(O)O^-$  is the aminocarboxylic anion,

~~m is an integer of at least from 3 to 7,~~

n is an integer from 2 to 12.

2. (Currently amended) A method for the production of a water-soluble compound according to claim 1, characterized in that an amino acid in the form of potassium or sodium salt is introduced into an o-dichlorobenzene solution of fullerene, then a solubilizer selected from the group of polyethylene oxides is added: polyethylene glycols with a molecular weight of 150 to 400 and higher, and also dimethyl ethers of polyethylene glycols or 18-crown-6, wherein the amount of the amino acid should be more than 50 times that of fullerene and the synthesis is carried out at a temperature of 60—80°C.

3. (Previously presented) A pharmaceutical composition for inhibiting the membrane virus reproduction, characterized in that it contains a water-soluble compound according to claim 1 in an effective amount and pharmaceutically acceptable fillers.

4. (Original) A pharmaceutical composition for inhibiting the membrane virus reproduction according to claim 3, characterized in that it is prepared in the form of tablets, capsules, a solution for injections, suppositories.

5. (Currently amended) A method for inhibiting membrane virus reproduction, characterized in that the pharmaceutical composition according to claim 3 is used for the suppression of viruses when treating diseases caused by at least one of HIV, herpes viruses, and hepatitis C virus.

6. (Currently Amended) A method for inhibiting membrane virus reproduction, characterized in that the pharmaceutical composition according to claim 4 is used for the suppression of viruses when treating diseases caused by at least one of HIV, herpes viruses, and hepatitis C virus.

7. (Previously Presented) A compound according to claim 1, wherein said fullerene polycarboxylic anion is one wherein m is 5

8. (Previously Presented) A compound according to claim 1, wherein said fullerene polycarboxylic anion is one wherein n is an integer from 4 to 6.

9. (Previously Presented) A compound according to claim 1, wherein said fullerene polycarboxylic anion is one wherein n is 6.

10. (Previously Presented) A compound according to claim 7, wherein said fullerene polycarboxylic anion is one wherein n is 6.

11. (Previously Presented) A compound according to claim 1, wherein m is an integer from 3 to 5.

12. (Previously Presented) A compound according to claim 1 wherein m is 3.